Posted by Michael Wonder on 18 Oct 2023
Bimzelx approved by the US FDA for the treatment of adults with moderate to severe plaque psoriasis
18 October 2023 - Approval is supported by three Phase 3 trials where bimekizumab consistently delivered fast, complete and lasting levels of skin clearance up to one year, and was generally well tolerated.
UCB announced today that the US FDA has approved Bimzelx (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
